OTCMKTS:NVZMY Novozymes A/S (NVZMY) Stock Price, News & Analysis $66.74 -0.46 (-0.68%) As of 11/12/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsNews and TrendsOwnershipSEC FilingsShort Interest About Novozymes A/S Stock (OTCMKTS:NVZMY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novozymes A/S alerts:Sign Up Key Stats Today's Range$66.67▼$67.3250-Day Range$62.09▼$71.9352-Week Range$49.90▼$75.27Volume19,582 shsAverage Volume42,756 shsMarket Capitalization$27.67 billionP/E Ratio37.75Dividend Yield0.58%Price TargetN/AConsensus RatingBuy Company Overview Novozymes A/S was a Denmark-based biotechnology company that developed and produced enzymes and microorganisms for industrial and consumer applications. Its solutions were used in areas including household care, food and beverages, agriculture, animal health and bioenergy. The company’s products included enzymes used in detergents, baking, brewing and biofuel production, as well as microbial solutions for agricultural and other industrial processes. Novozymes served customers in markets around the world. In January 2024, Novozymes merged with Danish bioscience company Chr. Hansen to form Novonesis. Novozymes’ former businesses became part of the combined company.AI Generated. May Contain Errors. Read More Novozymes A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreNVZMY MarketRank™: 1.731020942405 of 5 starsNovozymes A/S scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingBuy Consensus RatingNovozymes A/S has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNovozymes A/S has received no research coverage in the past 90 days.Read more about Novozymes A/S's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth7.76% Earnings GrowthEarnings for Novozymes A/S are expected to grow by 7.76% in the coming year, from $2.45 to $2.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novozymes A/S is 37.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Novozymes A/S is 37.75, which means that it is trading at a more expensive P/E ratio than the Materials sector average P/E ratio of about 27.12.Price to Earnings Growth RatioNovozymes A/S has a PEG Ratio of 3.01. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovozymes A/S has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Novozymes A/S has been sold short.Short Interest Ratio / Days to CoverNovozymes A/S has a short interest ratio ("days to cover") of 0.19, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novozymes A/S has recently decreased by 26.95%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldNovozymes A/S has a dividend yield of 0.58%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthNovozymes A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novozymes A/S is 23.08%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novozymes A/S will have a dividend payout ratio of 14.77% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.Read more about Novozymes A/S's dividend. News and Social Media0.6 / 5News SentimentN/A News SentimentNovozymes A/S has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Materials companies. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novozymes A/S insiders have not sold or bought any company stock.Percentage Held by Institutions0.03% of the stock of Novozymes A/S is held by institutions.Read more about Novozymes A/S's insider trading history. Receive NVZMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVZMY Stock News HeadlinesTranscript : Novozymes A/S, Nine Months 2026 Earnings Call, Nov 05, 2026November 5, 2026 | marketscreener.comMNovozymes A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out. | Weiss Ratings (Ad)Novozymes A/S (NVZMY) Q2 2026 Earnings Call TranscriptAugust 20, 2026 | seekingalpha.comNovonesis (Novozymes) B ADR NVZMYAugust 5, 2026 | morningstar.comMNovozymes AS DRC (NVZMY)June 24, 2026 | investing.comA Look At Novozymes (CPSE:NSIS B) Valuation After Recent Share Price WeaknessMay 14, 2026 | uk.finance.yahoo.comNovozymes Dividend Increase And Valuation Discount Catch Investor AttentionApril 4, 2026 | finance.yahoo.comSee More Headlines NVZMY Stock Analysis - Frequently Asked Questions How have NVZMY shares performed this year? Novozymes A/S's stock was trading at $63.95 on January 1st, 2026. Since then, NVZMY shares have increased by 4.4% and is now trading at $66.74. How were Novozymes A/S's earnings last quarter? Novozymes A/S (OTCMKTS:NVZMY) released its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.74 by $0.26. The biotechnology company earned $1.28 billion during the quarter, compared to analysts' expectations of $1.28 billion. Novozymes A/S had a trailing twelve-month return on equity of 6.56% and a net margin of 15.59%. Does Novozymes A/S have any subsidiaries? The following companies are subsidiaries of Novozymes A/S: PrecisionBiotics Group Limited, OrganoBalance GmbH, Pacific Vet Group-USA, Allopartis, TJ Technologies, Iogen Bio-Products, Natural Industries, and others. How do I buy shares of Novozymes A/S? Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novozymes A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novozymes A/S investors own include NVIDIA (NVDA), Novo Nordisk A/S (NVO), Procter & Gamble (PG), AT&T (T), Nestle (NSRGY), Alphabet (GOOG) and Accenture (ACN). Company Calendar Last Earnings11/05/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMaterials Industry Chemicals Sub-IndustryN/A Current SymbolOTCMKTS:NVZMY Previous SymbolOTC:NVZMY CIK1131345 Webwww.novonesis.com Phone(454) 446-0000Fax45-4446-9999Employees10,933Year Founded2000Profitability EPS (Trailing Twelve Months)$1.69 Trailing P/E Ratio37.75 Forward P/E Ratio25.28 P/E Growth3.01Net Income$660.28 million Net Margins15.59% Pretax Margin18.82% Return on Equity6.56% Return on Assets4.37% Debt Debt-to-Equity Ratio0.25 Current Ratio1.74 Quick Ratio1.04 Sales & Book Value Annual Sales$4.70 billion Price / Sales5.88 Cash Flow$1.67 per share Price / Cash Flow40.06 Book Value$26.23 per share Price / Book2.54Miscellaneous Outstanding Shares414,550,000Free FloatN/AMarket Cap$27.67 billion OptionableNot Optionable Beta0.86 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:NVZMY) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novozymes A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novozymes A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
